Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 master protocol of plixorafenib in BRAF-altered cancers
NL-OMON61071Phase 2Recruiting
- Sponsor
- Fore Biotherapeutics
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of plixorafenib in Nonhematologic neoplasms and central nervous system primary tumor, sponsored by Fore Biotherapeutics. Primary endpoints: Objective Response Rate and Pharmacokinetics. Started May 2026; status: recruiting.
02
Drugs
plixorafenib
03
Conditions
Nonhematologic neoplasmscentral nervous system primary tumor
Beyond the preview
Go deeper on NL-OMON61071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61071.